Bausch Health (LTS:0QYW) Research & Development: CHF504 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0QYW Bausch Health Companies Inc LTS:0QYW
65 GF Score
Price CHF122.94
GF Value CHF157.98
! 3 Warning Signs
View Full Analysis

What is Bausch Health Research & Development?

Bausch Health LTS:0QYW 65 Research & Development is CHF504 Mil as of Jun. 2026. GuruFocus rates LTS:0QYW with a GF Score™ of 65/100 and a GF Value™ of CHF157.98. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Bausch Health's Research & Development for the three months ended in Jun. 2026 was CHF138 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was CHF504 Mil.

Bausch Health  (LTS:0QYW) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Bausch Health Research & Development Related Terms

Bausch Health Research & Development Historical Data

* Premium members only.

The historical data trend for Bausch Health's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bausch Health Research & Development Chart

Bausch Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 435.63 492.82 522.34 549.23 501.25

Bausch Health Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 129.30 196.64 40.64 128.33 138.28
LTS:0QYW
65GF Score
Bausch Health Companies Inc LTS:0QYW
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bausch Health Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF504 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of CHF504 Mil mean?
Bausch Health (LTS:0QYW) has a Research & Development of CHF504 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Bausch Health and its competitors.
Is Bausch Health's Research & Development too high?
Bausch Health's current Research & Development is CHF504 Mil. Overall, Bausch Health has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's Research & Development compare to ZTS?
Bausch Health's Research & Development of CHF504 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Bausch Health and its competitors. Bausch Health's current Research & Development is CHF504 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Bausch Health (LTS:0QYW) has a current Research & Development of CHF504 Mil. The stock's GF Value™ is CHF157.98, compared to a current price of CHF122.94 — trading 22.2% below its estimated fair value. The current Research & Development is CHF504 Mil. Bausch Health's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Bausch Health (LTS:0QYW), the current Research & Development is CHF504 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bausch Health (LTS:0QYW) Overvalued in 2026?

Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued. The current stock price of CHF122.94 is trading 22.2% below its estimated GF Value™ of CHF157.98.

Key valuation signals for LTS:0QYW:

  • Research & Development: CHF504 Mil
  • GF Value™: CHF157.98 vs. price of CHF122.94 (22.2% below fair value)
  • GF Score™: 65/100 with 3 warning signs

No single metric tells the full story. See the LTS:0QYW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bausch Health Business Description

Address 2150 St Elzear Boulvard West, Laval, QC, CAN, H7L 4A8
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
65GF Score

Get the complete analysis for LTS:0QYW

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF122.94
Price
CHF157.98
GF Value